https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/gosh-researchers-receive-ucl-business-award/
GOSH researchers receive UCL Business Award
23 Jun 2017, 12:57 p.m.
Professors Bobby Gasper and Adrian Thrasher, both members of the BRC senior management team, have been awarded the UCL Business Award, in recognition of their work on the spin-out company Orchard Therapeutics.
Orchard is a biotechnology company focused on the development and commercialization of gene therapy medicines for children with rare diseases. It was launched in May 2016 with support from UCL Business and a £21 million investment from F-Prime Capital Partners.
Orchard focusses on restoring normal gene function in immunodeficiencies, metabolic diseases and haematological disorders and builds on GOSH researchers' expertise in stem, cell and gene therapies. Read more.
Professor Gaspar is Deputy Director of the NIHR GOSH BRC and Professor Thrasher is BRC Theme Lead for Gene, Stem and Cellular Therapies.
New Director Designate announced for NIHR GOSH Biomedical Research Centre
Professor Paul Gissen has been announced as the Director Designate of the NIHR GOSH Biomedical Research Centre.
Study linking data from 85% of children in England compares rare cardiac risks post-COVID vs vaccination
A major study which analysed anonymised health records from over 14 million children in England has shown that rare heart and inflammatory issues were more likely - and lasted longer - after COVID-19 infection than after vaccination.
Celebrating research that transforms lives
The 2025 NIHR GOSH BRC Showcase recently celebrated some incredible progress made in paediatric research.
Landmark gene therapy study shows safety for children
Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the long-term safety and efficacy of the curative treatment.